Oakio Introduces Innovative Proshield WPC Beam for Sustainable Architecture
Oakio, a leading manufacturer in Wood-Plastic Composite (WPC) materials, introduces its advanced Proshield WPC Beam, designed to meet the growing demand for sustainable and durable construction solutions. As Europe embraces eco-friendly building practices, Oakio's Proshield WPC Beam emerges as an ideal choice for architects and builders aiming to combine environmental responsibility with high performance.
Superior Composition for Enhanced Durability
The Proshield WPC Beam stands out due to its unique composition. Crafted from a blend of high-density polyethylene (HDPE) and finely ground recycled oak wood fibers, the beam offers a perfect marriage of natural aesthetics and industrial strength. What sets the Proshield series apart is its protective outer layer, made from the same material used in golf balls. This robust co-extruded layer envelops the wood-plastic core, significantly enhancing the beam’s resistance to weather, moisture, and UV radiation, ensuring long-lasting durability even in harsh outdoor environments.
"Our Proshield WPC Beam is engineered for maximum performance," says Juno Zhong, Marketing Director at Oakio. "The protective shield not only improves the beam's lifespan but also reduces maintenance needs, making it an eco-friendly alternative to traditional wood."
Customization at Its Best
Oakio's Proshield WPC Beam offers extensive customization options, making it adaptable to various architectural styles. Available in multiple profiles, textures, and colors, the beam can seamlessly integrate into both modern and traditional designs. Whether a smooth, polished look or a more rustic, wood-grain appearance is desired, Oakio's Proshield WPC Beam provides the flexibility needed to achieve specific design goals.
Sustainability: A Greener Choice
Aligned with Oakio's commitment to sustainability, Oakio WPC Beam is carefully crafted from eco-friendly materials, consisting of 55% oak wood fiber, 35% plastic resin, and 10% additives. This focus on environmental responsibility ensures that every WPC beam maintains exceptional quality and performance while promoting a more sustainable future.
About Oakio
Oakio is a pioneering manufacturer of Wood-Plastic Composite products, offering a wide range of sustainable and innovative composite building materials. With a focus on quality and environmental responsibility, Oakio is dedicated to pushing the boundaries of modern construction with products like the Proshield WPC Beam, designed to meet the evolving needs of the industry. For more information about Oakio Proshield WPC Beam or to explore Oakio's full range of outdoor products, visit www.oakio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821014419/en/
Contacts
Juno Zhong
info@oakio.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research7.3.2025 20:16:00 CET | Press Release
Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307777605/en/ On the Proteintech website (ptglab.com), researchers can explore antibody binding sites with the new interactive 3D epitope viewer. (Photo: Business Wire) The 3D Epitope Mapping is a state-of-the-art solution that utilizes a combination of experimental techniques, including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized
I Squared Capital Appoints Philippe Lenoble and Bogdan Ciobotaru as Managing Directors7.3.2025 16:32:00 CET | Press Release
I Squared Capital, a leading independent global infrastructure investment firm, today announced two senior appointments to its investment and asset management teams in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306212222/en/ Philippe Lenoble, Managing Director, I Squared (Photo: Business Wire) Philippe Lenoble will join the investment team as Managing Director, reporting to Mohamed El Gazzar, Senior Partner. Bogdan Ciobotaru will join the asset management team as Managing Director reporting to Maxime Jacqz, Managing Director, who leads asset management in Europe. The demands for new and improved infrastructure requires investors to balance the increasing opportunities with the right resourcing to manage the increased scale and complexity. I Squared is committed to expanding its investment and asset management capabilities in a thoughtful and deliberate way to seize this opportunity and deliver value for its pa
Vertex Announces UK MHRA Approval of ALYFTREK ® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis7.3.2025 16:02:00 CET | Press Release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor),a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. “For more than 20 years we have been focused on discovering medicines that treat the underlying cause of the disease with the goal of helping people live longer and better lives. The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “The deutivacaftor/tezacaftor/vanzacafto
Interactive Brokers Nominates Lori Conkling to its Board of Directors7.3.2025 16:00:00 CET | Press Release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the nomination of Lori Conkling as an independent director of the firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307601860/en/ Lori Conkling (Photo: Business Wire) Ms. Conkling will bring a wealth of knowledge to Interactive Brokers. As Head of TV & Film Licensing at Netflix, she oversees content acquisition and business development for their ad-free and ad-supported platforms. Before joining Netflix, she held leadership positions at Google, including Global Head of TV, Film and Sports for YouTube and YouTube TV. “We are pleased to nominate Lori to the Board of Directors and look forward to leveraging her expertise to enhance our profile across the media landscape,” said Thomas Peterffy, Founder and Chairman of Interactive Brokers. “A successful senior executive with over 25 years of experience in the media space, Ms. Conkling will
Innovaderm Research Rebrands as Indero, a Dual-Focus CRO7.3.2025 15:00:00 CET | Press Release
Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields. Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculoskeletal system. Rheumatology and dermatology therefore often overlap in diagnosing and managing diseases where the immune system plays a central role, and Indero will harness its expertise to deliver comprehensive, patient-focused solutions for these markets. The company’s full-service approach can support both early and late-phase trials across both specialties. Dr Robert Bissonnette, Founder and Executive Chairman, commented: “As Innovaderm, we have served the dermatology clinical research community for 25 years, building
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom